POLISCOPE
Back to bills

The civic record

Read. Follow. Verify.
High Impact

New Jersey bill requires health insurers and Medicaid to cover Alzheimer's testing and treatments

Original title: Requires health insurance and Medicaid coverage for testing and treatments to slow progression of Alzheimer's disease and related disorders.

Last action · May 4, 2026: Introduced in the Senate, Referred to Senate Commerce CommitteeSponsors: Gordon Johnson and 22 others

Companion · A 5062same policy, Assembly version
Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Public stanceCommunity reactions are separate from the official record and reporting.

What This Bill Would Do

Senate Bill 4073 requires health insurance contracts, state health benefits programs, and the state Medicaid program to cover medically necessary diagnostic testing and FDA-approved treatments or medications that slow the progression of Alzheimer's disease and related disorders. The bill prohibits insurers from requiring for these treatments and sets an effective date on the 180th day following enactment.

Why it matters

Patients enrolled in New Jersey state-regulated health plans or Medicaid gain mandatory insurance coverage for Alzheimer's progression-slowers and diagnostic testing without facing protocols.

Who It Would Affect

Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.

Directly affected

Patients with Alzheimer's disease and related disorders

Patients gain guaranteed health insurance and Medicaid coverage for medically necessary diagnostic testing and FDA-approved progression-slowing medications without step therapy requirements.

Directly affected

Health insurance carriers

Insurers must update their policies, contracts, and health benefits plans to provide coverage for Alzheimer's diagnostic testing and progression-slowing treatments in accordance with FDA labels.

Directly affected

State Health Benefits Commission and School Employees’ Health Benefits Commission

The commissions must ensure that every contract they purchase provides coverage for medically necessary diagnostic testing and FDA-approved Alzheimer's treatments.

Directly affected

Medicaid program

The Medicaid program must provide coverage for Alzheimer's diagnostic testing and progression-slowing treatments, and the Department of Human Services must seek necessary federal waivers.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

What types of insurance plans are affected by this bill?
The bill affects contracts, medical service corporation contracts, health service corporation contracts, individual and group health insurance policies, individual and small employer health benefits plans, HMO contracts, the State and School Employees' Health Benefits Programs, and the state Medicaid program.
Does the bill allow insurance companies to require step therapy for Alzheimer's treatments?
No. The bill explicitly prohibits coverage of FDA-approved treatments or medications prescribed to slow the progression of Alzheimer's disease or related disorders from being subject to any requirements.
When will these insurance requirements take effect if passed?
The act takes effect on the 180th day following the date of enactment and applies to contracts delivered, issued, executed, or renewed on or after that date.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

Currently in committee. The next step in the legislative lifecycle is Floor Vote.

Procedural history

1 action
  1. May 4, 2026SenateIntroduced
    Introduced in the Senate, Referred to Senate Commerce Committee

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Lobbying Activity

No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Sponsors

Connected Entities

Linda R. Greenstein, Joseph Pennacchio, Gordon M. Johnson and 12 more
PersonLinda R. Greenstein“Co-sponsor of the bill”Map →
PersonJoseph Pennacchio“Co-sponsor of the bill”Map →
PersonGordon M. Johnson“Senator representing District 37”Map →
OrganizationSchool Employees’ Health Benefits Commission“Must ensure covered contracts include Alzheimer's testing and treatments”Map →
OrganizationState Health Benefits Commission“Must ensure covered contracts include Alzheimer's testing and treatments”Map →
PersonVin Gopal“Co-sponsor of the bill”Map →
PersonParker Space“Co-sponsor of the bill”Map →
PersonAnthony M. Bucco“Senator representing District 25”Map →
PersonAndrew Zwicker“Co-sponsor of the bill”Map →
PersonLatham Tiver“Co-sponsor of the bill”Map →
OrganizationDepartment of Human Services“Administers Medicaid and must ensure coverage for Alzheimer's testing and treatm”Map →
PersonKristin M. Corrado“Co-sponsor of the bill”Map →
PersonDouglas J. Steinhardt“Co-sponsor of the bill”Map →
PersonPatrick J. Diegnan, Jr.“Co-sponsor of the bill”Map →
PersonBrian P. Stack“Co-sponsor of the bill”Map →

Sources

Open source document

njleg.state.nj.us

Analysis Score

0–100
  • Significance75
    How much this matters to a regular citizen
  • Controversy25
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz40
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record